The historical rank and industry rank for Nanoform Finland's ROE % or its related term are showing as below:
STU:4YL'
s ROE % Range Over the Past 10 Years
Min: -3859.26 Med: -36.9 Max: -25.71
Current: -34.51
During the past 10 years, Nanoform Finland's highest ROE % was -25.71%. The lowest was -3,859.26%. And the median was -36.90%.
STU:4YL's ROE % is ranked better than 52.16% of 1252
companies
in the Biotechnology industry
Industry Median: -38.145
vs STU:4YL: -34.51
Nanoform Finland (STU:4YL) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Nanoform Finland ROE % Related Terms
Nanoform Finland ROE % Historical Data
* Premium members only.
The historical data trend for Nanoform Finland's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Nanoform Finland's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nanoform Finland ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nanoform Finland's ROE % distribution charts can be found below:
* The bar in red indicates where Nanoform Finland's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Nanoform Finland (STU:4YL) has a ROE % of -33.24% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Nanoform Finland and its competitors. According to the industry distribution chart, Nanoform Finland ranks #599 out of 1252 companies in the Biotechnology industry, placing it in the top 47.8%.
Is Nanoform Finland's ROE % too high?
Nanoform Finland's current ROE % is -33.24%. Based on the distribution chart, Nanoform Finland ranks #599 out of 1252 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nanoform Finland has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nanoform Finland's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanoform Finland ranks #599 out of 1252 companies for ROE %. This puts Nanoform Finland in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Nanoform Finland and its competitors. Nanoform Finland's current ROE % is -33.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanoform Finland stock overvalued right now?
Based on GuruFocus' analysis, Nanoform Finland (STU:4YL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.77, compared to a current price of €0.77 — trading 56.3% below its estimated fair value. The current ROE % is -33.24%. Nanoform Finland's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Nanoform Finland (STU:4YL), the current ROE % is -33.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nanoform Finland (STU:4YL) Overvalued in 2026?
Based on GuruFocus' analysis, Nanoform Finland stock appears to be undervalued.
The current stock price of €0.77 is trading 56.3% below its estimated GF Value™ of €1.77.
GuruFocus considers Nanoform Finland to be Possible Value Trap.
Key valuation signals for STU:4YL:
ROE %: -33.24%
GF Value™: €1.77 vs. price of €0.77 (56.3% below fair value)
No single metric tells the full story. See the STU:4YL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nanoform Finland PLC is a nanoparticle medicine-enabling company. The company works together with pharma and biotech partners to reduce attrition in clinical trials and enhance their molecules' formulation performance through its nano-forming services. Its patented and scalable Controlled Expansion of Supercritical Solutions (CESS) technology produces nano-formed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Its technology provides novel opportunities in many value-enhancing drug delivery applications. Geographically, the company generates maximum revenue from Europe, followed by the United States and other regions.
67GF Score
Get the complete analysis for STU:4YL
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4YL has been successfully added to your 
